Schubert & Co’s Allogene Therapeutics ALLO Stock Holding History

Schubert & Co’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$5	–	93
2023 Q1	$5	Sell	1 -9	-90%	-$58	﹤0.01%	1670
2022 Q4	$63	Buy	10 +1	+11%	+$9	﹤0.01%	1601
2022 Q3	$0	Buy	+9	New	+$122	﹤0.01%	1362

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schubert & Co's ALLO Position: Q2 2023 in Review

Schubert & Co sold out of Allogene Therapeutics (ALLO) in Q2 2023, closing a stake of 1 share — an estimated $5 sold.

Schubert & Co first reported a position in ALLO in Q3 2022 and held it in 3 quarters. The position peaked at $63 in Q4 2022. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

Schubert & Co reported no remaining Allogene Therapeutics position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 1 Allogene Therapeutics share in Q2 2023, an estimated $5.
Schubert & Co first reported a position in Allogene Therapeutics in Q3 2022 and held it in 3 quarters.
Schubert & Co's Allogene Therapeutics position peaked at $63 in Q4 2022.
171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.